Next-generation sequencing (NGS) analysis revealed copy number loss of <i>SMARCB1</i> and a novel <i>GSTT1::IGLC7</i> fusion in the tumor, while no other gene rearrangements, including those involving <i>EWSR1</i>, <i>NR4A3</i>, or <i>FUS</i>, were detected. The gene discussed is FUS; the disease is neoplasm.